← Leaderboards
Darren Richard Carpizo
Rbhs -Cancer Institute Of New Jersey
$3,102,872
Attributed
$3,602,027
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $644.5K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,602,027 · 4
By mechanism
R01$2,498,244 · 2
K08$744,571 · 1
R21$359,212 · 1
Top collaborators
- Samuel I Gunderson2 shared
- Scott Andrew Gerber1 shared
Most similar at Rbhs -Cancer Institute Of New Jersey
Same institution · by research overlap
- Jinesh Shailesh Gheeya$147,631
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignMalignant NeoplasmsDoseMouse ModelMutationIn VivoLeadMutateGenesProteinsPharmaceutical PreparationsMediatingProgramsDrug TargetingAreaLaboratoriesChelating AgentsIonsAffinityAntineoplastic AgentsMetalsDna Binding DomainCancer CellAlleles
Grant awards (13)
Targeting Intrinsic and Extrinsic Barriers to Treat Metastatic Pancreatic Cancer$639,098
R01 · FY2025 · CA
Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancerDrugs$394,954
R01 · FY2020 · CA · contact PI
Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancer Drugs$353,785
R01 · FY2019 · CA · contact PI
Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancer Drugs$365,277
R01 · FY2018 · CA · contact PI
Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancer Drugs$365,277
R01 · FY2017 · CA · contact PI
Exploration of a Mutant p53 Reactivating Compound$158,958
K08 · FY2017 · CA · contact PI
Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancer Drugs$379,853
R01 · FY2016 · CA · contact PI
Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cancer$155,875
R21 · FY2016 · CA
Exploration of a Mutant p53 Reactivating Compound$108,739
K08 · FY2016 · CA · contact PI
Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cancer$203,337
R21 · FY2015 · CA
Exploration of a Mutant p53 Reactivating Compound$158,958
K08 · FY2015 · CA · contact PI
Exploration of a Mutant p53 Reactivating Compound$158,958
K08 · FY2014 · CA · contact PI
Exploration of a Mutant p53 Reactivating Compound$158,958
K08 · FY2013 · CA · contact PI